Kissei stock: Japan questions Tavneos data reliability for Kissei stock

Published on 10/23/2026 at 00:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Japan questions Tavneos data after 23 deaths linked to liver dysfunction. For Kissei stock, results are due November 4, 2026.

Regulatory pressure and upcoming results

Japan questioned Tavneos data reliability on October 22, 2026 after 23 deaths linked to liver dysfunction.
Kissei had acquired 106,400 shares for JPY 426,244,500 during September 2026.
Kissei Pharmaceutical is scheduled to report second-quarter fiscal 2027 results on November 4, 2026.

Kissei, JP3240600001, Illustration mit AI erstellt.

Kissei Pharmaceutical (JP3240600001) faces a Japanese regulatory review after 23 Tavneos users died from liver dysfunction, with six cases retaining a possible drug relationship, according to The Japan Times on October 22, 2026. The report says Japan's health ministry may decide on administrative action, potentially including withdrawal of the drug's approval, by the end of 2026.

Tavneos review adds regulatory risk

The Pharmaceuticals and Medical Devices Agency found reliability issues in clinical trial results submitted for Tavneos and judged them unsuitable as evidence of efficacy, PHARMA JAPAN reported on October 22, 2026. Medical institutions were asked to avoid starting new patients and to consider stopping treatment or switching existing patients to alternatives.

The scale of the safety issue has widened from the 20 deaths Kissei reported in May 2026 to 23 deaths cited by the ministry in October, a 15.00 percent increase. Tavneos launched in Japan in June 2022, making the review relevant to a product that has been marketed domestically for more than four years, according to The Japan Times.

What does Tavneos mean for earnings?

The product issue matters because Kissei cut its Tavneos sales outlook in 2026 as prescriptions weakened. The company's capital-allocation response continued in September, when it bought 106,400 shares for JPY 426,244,500, bringing cumulative purchases to 181,900 shares and JPY 730,038,500 by September 30, according to Japan IR.

November 4 results are next

Kissei is scheduled to report second-quarter fiscal 2027 results on November 4, 2026, according to Simply Wall St. That release should show how the Tavneos setback affects the six-month sales outlook and whether other products can offset the pressure.

Regulatory decision remains ahead

The immediate investment question is whether Japan limits Tavneos permanently and how Kissei accounts for the commercial impact. The ministry's administrative decision is expected by the end of 2026, keeping regulatory developments ahead of the November results as a central company-specific risk.